tements. There are a number of important factors
that could cause Rigel's results to differ materially from those indicated
by these forward-looking statements, including risks associated with the
timing and success of clinical trials and the commercialization of product
candidates, as well as other risks detailed from time to time in Rigel's
reports filed with the Securities and Exchange Commission, including its
Form 10-Q for the quarter ended June 30, 2007. Rigel does not undertake any
obligation to update forward-looking statements.
Contact: Ryan D. Maynard
Phone: 650.624.1284
Email: invrel@rigel.com
Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
Phone: 650.430.3777
Email: susan@alchemyemail.com
STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
Three Months Ended Nine Months Ended
September 30, September 30,
2007 2006 2007 2006
(unaudited) (unaudited)
Revenues:
Contract revenues $- $6,127 $4,600 $30,345
Operating expenses:
Research and development
(see Note A) 15,372 14,050 48,404 41,966
General and administrative
(see Note A) 5,054 4,804 15,466 14,532
Total operating expenses 20,426 18,854 63,870 56,498
Loss from operations (20,426) (12,727) (59,270) (26,153)
Interest income, net 1,482 1,345 4,000 3,972
Net loss $(18,944) $(11,382) $(55,270) $(22,181)
Net loss per share, basic and
diluted
'/>"/>
SOURCE Rigel Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related medicine news :1.
HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness2.
CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael3.
UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West4.
HEI, Inc. Announces Sale of RFID Division Assets5.
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)6.
Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference7.
Z Trim Announces Revocation of Gregory Halpern Severence Agreement8.
Brooke Franchise Corporation Announces Selected July Results9.
Manor Care, Inc. Announces Record Date for Special Stockholder Meeting10.
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)11.
Planet Technologies Announces Agreement to Acquire Antigen Laboratories